Single-Institution Retrospective Review of Patients With Recurrent Glioblastoma Treated With Bevacizumab in Clinical Practice

Health Science Reports
doi 10.1002/hsr2.114
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Bevacizumab and Chemotherapy for Recurrent Glioblastoma: A Single-Institution Experience

Neurology
Neurology
2009English

Quantification of Edema Reduction Using Differential Quantitative T2 (DQT2) Relaxometry Mapping in Recurrent Glioblastoma Treated With Bevacizumab

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2011English

Radiosurgery for Recurrent Glioblastoma Multiforme: A Single Institution Experience

Canadian Journal of Neurological Sciences
MedicineNeurology
2014English

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology
Neurology
2014English

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Management of Patients Treated With Pertuzumab in the Australian Clinical Practice Setting

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy